NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6560
-0.0570 (-7.99%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.7130
Open0.7320
Bid0.6700 x 1000
Ask0.7349 x 800
Day's Range0.6453 - 0.7320
52 Week Range0.6453 - 73.0000
Volume1,055,372
Avg. Volume1,551,332
Market Cap15.57M
Beta (3Y Monthly)2.50
PE Ratio (TTM)N/A
EPS (TTM)-14.1700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • PR Newswire5 days ago

    Neovasc Announces Positive 12-year Follow-up Data for Neovasc Reducer™ as Published in JACC

    "This new data demonstrates the ultimate success of the Reducer for the treatment of refractory angina, with proof of sustained efficacy and complete safety for these patients 12 years after implantation," commented Fred Colen, Neovasc's President and Chief Executive Officer.

  • CNW Group5 days ago

    Neovasc Announces Positive 12-year Follow-up Data for Neovasc Reducer™ as Published in JACC

    "This new data demonstrates the ultimate success of the Reducer for the treatment of refractory angina, with proof of sustained efficacy and complete safety for these patients 12 years after implantation," commented Fred Colen , Neovasc's President and Chief Executive Officer.

  • PR Newswire26 days ago

    JACC: Cardiovascular Interventions Publishes Peer Reviewed Article on Neovasc Reducer™ Patient Case

    "Receiving such positive news on the outcome for this patient after the Reducer treatment, while still at an angina class III level despite optimal anginal drug treatments before the Reducer treatment, is a testament to the opportunity for our Reducer," commented Fred Colen, Neovasc's President and Chief Executive Officer.

  • CNW Group26 days ago

    JACC: Cardiovascular Interventions Publishes Peer Reviewed Article on Neovasc Reducer™ Patient Case

    "Receiving such positive news on the outcome for this patient after the Reducer treatment, while still at an angina class III level despite optimal anginal drug treatments before the Reducer treatment, is a testament to the opportunity for our Reducer," commented Fred Colen , Neovasc's President and Chief Executive Officer.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Neovasc and Acadia Healthcare

    NEW YORK / ACCESSWIRE / November 14, 2018 / U.S. equities closed down on Wednesday as tech giant Apple closed near bear-market territory and another drop in oil prices raised concerns of a global economic ...

  • Associated Presslast month

    Neovasc: 3Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had a loss of 70 cents per share. Losses, adjusted for amortization costs and non-recurring costs, were 61 cents per share. The medical device company ...

  • PR Newswirelast month

    Neovasc Announces Third Quarter 2018 Financial Results

    VANCOUVER, Nov. 14, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today reported financial results for the third quarter ended September 30, 2018. As a result, the Company is now on a stronger foundation from which to continue advancing our product development, clinical and commercial programs for the Reducer and Tiara," said Fred Colen, President and Chief Executive Officer of Neovasc. Mr. Colen continued, "The Tiara clinical outcome data, which we have been regularly reporting on, is increasingly generating positive attention as a leading option for minimally invasive mitral valve replacement for patients suffering from severe mitral regurgitation.

  • CNW Grouplast month

    Neovasc Announces Third Quarter 2018 Financial Results

    VANCOUVER , Nov. 14, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today reported financial results for the third quarter ended September 30, 2018 . As a result, the Company is now on a stronger foundation from which to continue advancing our product development, clinical and commercial programs for the Reducer and Tiara," said Fred Colen , President and Chief Executive Officer of Neovasc. Mr. Colen continued, "The Tiara clinical outcome data, which we have been regularly reporting on, is increasingly generating positive attention as a leading option for minimally invasive mitral valve replacement for patients suffering from severe mitral regurgitation.

  • Benzingalast month

    Neovasc Q3 Earnings Preview

    Neovasc Inc. - Common Shares (NASDAQ: NVCN ) announces its next round of earnings this Wednesday, Nov. 14. Here is Benzinga's everything-that-matters guide for the Q3 earnings announcement. Earnings and ...

  • CNW Grouplast month

    Neovasc Announces Third Quarter 2018 Financial Results Conference Call and Webcast

    Neovasc Announces Third Quarter 2018 Financial Results Conference Call and Webcast

  • PR Newswirelast month

    Neovasc Announces Third Quarter 2018 Financial Results Conference Call and Webcast

    NASDAQ, TSX: NVCN VANCOUVER , Nov. 7, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter ...

  • ACCESSWIRE2 months ago

    3 Healthcare Stocks To Watch On Tuesday

    Healthcare stocks have helped during times like these. Three healthcare stocks to watch this week include Premier Health Group, Inc. (PHGRF)(PHGI.CN), Neovasc Inc. (NVCN), and Regulus Therapeutics Inc. (RGLS). Premier Health Group, Inc. (PHGRF)(PHGI.CN), continued to trade higher this week.

  • Benzinga2 months ago

    Neovasc Broadcasts Surgery With Mitral Valve Device Live At Medical Conference

    Neovasc said its Tiara transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 32nd Annual European Association for Cardio-Thoracic Surgery Meeting held in Milan, Italy. Tiara is being developed by Neovasc for treating mitral regurgitation, a condition affecting about 4 million patients in the U.S.

  • PR Newswire2 months ago

    Neovasc Announces Successful Tiara™ "Live Case" at the 32nd Annual EACTS 2018 Meeting

    VANCOUVER, Oct. 22, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 32nd Annual European Association for Cardio-Thoracic Surgery Meeting ("EACTS 2018"), held October 18-20 in Milan, Italy. In a live case broadcast to the main arena of the conference, Dr. Lenard Conradi and Dr. Ulrich Schaefer of University Medical Center Hamburg-Eppendorf (Hamburg, Germany) successfully implanted a 40mm Tiara transcatheter mitral valve in a patient suffering from severe mitral regurgitation ("MR").

  • CNW Group2 months ago

    Neovasc Announces Successful Tiara™ "Live Case" at the 32nd Annual EACTS 2018 Meeting

    VANCOUVER , Oct. 22, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 32nd Annual European Association for Cardio-Thoracic Surgery Meeting ("EACTS 2018"), held October 18-20 in Milan, Italy . In a live case broadcast to the main arena of the conference, Dr. Lenard Conradi and Dr. Ulrich Schaefer of University Medical Center Hamburg-Eppendorf ( Hamburg, Germany ) successfully implanted a 40mm Tiara transcatheter mitral valve in a patient suffering from severe mitral regurgitation ("MR").

  • CNW Group2 months ago

    Neovasc Announces Publication of a Peer-Reviewed Article on Tiara™ Cases in Circulation: Cardiovascular Interventions

    VANCOUVER , Oct. 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that an original article was published in Circulation: Cardiovascular Interventions titled 'Transcatheter Mitral Valve Replacement in Patients With Previous Aortic Valve Replacement', which reports for the first time ever the experience of transcatheter mitral valve replacement ("TMVR") using Neovasc's Tiara™ ("Tiara") valve in patients with previous aortic valve replacement. The Tiara is a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation ("MR"), one of the most prevalent valvular heart diseases in western countries.  Tiara is not currently approved for commercial sale in any geographies.

  • PR Newswire2 months ago

    Neovasc Announces Publication of a Peer-Reviewed Article on Tiara™ Cases in Circulation: Cardiovascular Interventions

    VANCOUVER, Oct. 16, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that an original article was published in Circulation: Cardiovascular Interventions titled 'Transcatheter Mitral Valve Replacement in Patients With Previous Aortic Valve Replacement', which reports for the first time ever the experience of transcatheter mitral valve replacement ("TMVR") using Neovasc's Tiara™ ("Tiara") valve in patients with previous aortic valve replacement. The Tiara is a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation ("MR"), one of the most prevalent valvular heart diseases in western countries.  Tiara is not currently approved for commercial sale in any geographies.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Neovasc and AcelRx Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 11, 2018 / Neovasc Inc. shares and AcelRx Pharmaceuticals shares were both winning big in Wedneday’s session on positive FDA developments. Neovasc headed higher on news that the FDA has granted Breakthrough Device designation to the Neovasc Reducer™. AcelRx Pharmaceuticals jumped after FDA staff had said the company's opioid painkiller was safe and effective for use based on resubmitted data.

  • Why Neovasc Stock (NVCN) Is Skyrocketing Today
    InvestorPlace2 months ago

    Why Neovasc Stock (NVCN) Is Skyrocketing Today

    Neovasc stock (NASDAQ:NVCN) is skyrocketing more than 26% on Wednesday as the company received good news from the U.S. Food and Drug Administration (FDA) regarding one of its latest products. The medical device company revealed that its Neovasc Reducer device that was designed to treat refractory angina was granted a Breakthrough Device designation by the FDA. The news caused Neovasc stock to skyrocket with volume soaring up to 21.2 million shares, which is considerably higher than the stock’s full-day average of just under 800,000 shares.

  • MarketWatch2 months ago

    Neovasc's stock rockets after 'Reducer' granted Breakthrough Device designation

    Shares of Neovasc Inc. shot up 37% to pace the Nasdaq's gainers in morning trade Wednesday, after the medical device company said it Neovasc Reducer device for the treatment of refactory angina was granted a Breakthrough Device designation by the Food and Drug Administration. Volume spiked up to 21.2 million shares, compared with the full-day average of just under 800,000 shares. Breakthrough Device designation allows for expedited development and review of a device that demonstrates "compelling potential" to provide more effective treatment for life-threatening diseases. "We will now start a process of further discussions and filings with the FDA, to obtain further guidance as to the regulatory pathway for entrance into the U.S. market," said Chief Executive Fred Colen. The stock has still plunged 94% year to date, while the S&P 500 has gained 6.6%.

  • PR Newswire2 months ago

    Neovasc Reducer™ Granted Breakthrough Device Designation from FDA

    VANCOUVER, Oct. 10, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer"), a medical device for the treatment of refractory angina, which is not currently approved for commercial sale in the U.S. The FDA grants Breakthrough Device designation in order to expedite the development and review of a device that demonstrates compelling potential to provide a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases.

  • CNW Group2 months ago

    Neovasc Reducer™ Granted Breakthrough Device Designation from FDA

    VANCOUVER , Oct. 10, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer"), a medical device for the treatment of refractory angina, which is not currently approved for commercial sale in the U.S. The FDA grants Breakthrough Device designation in order to expedite the development and review of a device that demonstrates compelling potential to provide a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases.

  • PR Newswire2 months ago

    Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

    VANCOUVER, Oct. 9, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification from the Nasdaq Hearings Panel (the "Panel") notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Nasdaq"), that it is in compliance with all other applicable continued listing requirements and that the Panel has determined to continue the listing of the Company's common shares on the Nasdaq. Words and phrases such as "continue", "may", "will" and "growing", and similar words or expressions, are intended to identify these forward-looking statements.

  • CNW Group2 months ago

    Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

    VANCOUVER , Oct. 9, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification from the Nasdaq Hearings Panel (the "Panel") notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Nasdaq"), that it is in compliance with all other applicable continued listing requirements and that the Panel has determined to continue the listing of the Company's common shares on the Nasdaq. Words and phrases such as "continue", "may", "will" and "growing", and similar words or expressions, are intended to identify these forward-looking statements.

  • MarketWatch2 months ago

    Neovasc shares soar 24% on news of positive data from first U.S. patient to use device to treat angina

    Neovasc Inc. shares soared more than 24% in premarket trade Wednesday, after the company announced positive data from the first U.S. patient to be implanted with a device to treat refractory angina. The Vancouver-based medical device company said its Neovasc Reducer produced positive data in a 12-week follow-up on the patient, who was able to walk several miles without symptoms and greatly reduce his use of nitroglycerin. Prior to using the device, the patient could walk only two blocks before experiencing angina and used nitroglycerin two to three times a week. The device has already achieved positive results in European studies, according to Chief Executive Fred Colen. Refractory angina affects 600,000 to 1.8 million Americans with up to 100,000 new cases emerging every year. Neovasc shares have fallen 96% in 2018 through Tuesday, while the S&P 500 has gained 9%.